Switching From Wegovy Pill to Injection: UK Prescribing Guide

Switching from Wegovy pill to injection is a question many patients on oral semaglutide are asking, particularly those who find the strict daily fasting requirements difficult to maintain. Both the Wegovy tablet and the Wegovy injection contain semaglutide and are approved for weight management in the UK, but they are absorbed, dosed and administered very differently. There is no simple milligram-for-milligram conversion between the two formulations, and the UK Summary of Product Characteristics does not provide a universal reverse conversion. A qualified prescriber must plan any switch based on individual treatment history.

Can You Switch From the Wegovy Pill to Wegovy Injections?

Switching is potentially possible but requires prescriber oversight, as the UK SmPC provides no standard reverse dose conversion from Wegovy tablets to injections and warns that the effect of switching cannot easily be predicted.

It may be possible to switch from the Wegovy pill to a Wegovy injection, but patients should not assume that there is a simple dose-for-dose conversion between the two formulations. Both contain the same active ingredient, semaglutide, and both are used for weight management, but they are taken, absorbed and dosed differently.

This distinction is particularly important because the current UK Summary of Product Characteristics (SmPC) does not provide a standard reverse conversion from each Wegovy tablet strength to a specific injection dose. The oral prescribing information gives one defined transition in the opposite direction: patients treated with semaglutide injection 2.4 mg once weekly can be transitioned to semaglutide tablets 25 mg once daily, starting the tablets one week after the last injection. However, this should not be reversed automatically to create a rule that every patient taking 25 mg tablets can simply start 2.4 mg injections.

In other words, the following assumption should not be made without a prescriber:

• 25 mg daily tablet = automatically start 2.4 mg weekly injection

The UK SmPC specifically warns that the effect of switching between semaglutide tablets and injections cannot easily be predicted.^[1][2] One reason is that oral semaglutide has greater variability in absorption than injected semaglutide.

This means the appropriate injection plan may depend on factors such as:

• the current Wegovy tablet strength

• how long the patient has taken that strength

• whether doses have been taken consistently

• whether the fasting instructions have been followed correctly

• treatment response

• current or previous side effects

• other medicines

• the reason for switching

• whether treatment has recently been interrupted

Someone taking 1.5 mg, 4 mg, 9 mg or 25 mg tablets should therefore not use the numbers on the packaging to calculate an injection dose. Likewise, a person who has previously used Wegovy injections should not automatically restart an old dose simply because they tolerated it in the past.

The standard Wegovy injection regimen for adults begins at 0.25 mg once weekly and increases over a 16-week period through 0.5 mg, 1 mg and 1.7 mg to the standard 2.4 mg maintenance dose. Current UK prescribing information also allows an increase to 7.2 mg once weekly for some adults with obesity where needed, after at least four weeks at 2.4 mg. However, that standard escalation schedule does not by itself answer which injection dose an individual should use after taking oral Wegovy.

The safest approach is to have the transition planned by a qualified prescriber based on the exact treatment history. Patients should not stop the tablet and start an injection at a self-selected dose.

Why There Is No Simple Tablet-to-Injection Dose Conversion

Oral semaglutide has approximately 1–2% bioavailability and highly variable absorption, meaning tablet and injection doses cannot be compared directly by milligrams.

The main reason switching from the Wegovy pill to an injection is not a straightforward mathematical calculation is that oral and injected semaglutide reach the body in very different ways.

A Wegovy injection is administered under the skin, known as subcutaneous administration. The Wegovy pill is swallowed and semaglutide is absorbed predominantly through the stomach with the help of an absorption-enhancing ingredient. The tablet has specific fasting instructions because food, water volume and timing can affect how much semaglutide is absorbed.

According to the UK oral SmPC, the estimated absolute bioavailability of oral semaglutide is approximately 1–2%, and absorption is variable.^[6][7] The tablet should be taken after fasting for at least 8 hours, swallowed whole with up to 120 mL of water, and followed by a wait of at least 30 minutes before food, drink or other oral medicines.^[5][6] Taking it with food or larger volumes of water can reduce absorption.

This helps explain why a 25 mg tablet is not equivalent to a 25 mg injection and why the tablet and injection numbers should never be compared directly.

The UK prescribing information reports that the average steady-state semaglutide concentration with a 25 mg daily tablet was approximately comparable to that seen with the 2.4 mg weekly injection in the populations studied. However, oral concentrations showed substantially greater variability. Comparable average exposure across a population does not mean that every individual taking 25 mg tablets will have the same exposure as every individual using 2.4 mg injections.

This variability is precisely why the SmPC says the effect of switching cannot easily be predicted.

There is another important consideration: semaglutide remains in the body for a long time. The oral SmPC reports an elimination half-life of approximately one week and states that semaglutide may remain in the circulation for approximately 5 to 7 weeks after the final 25 mg tablet dose.^[6][7]

This does not mean everyone needs a 5-to-7-week gap before starting an injection. The prescribing information does not establish such a universal waiting period, and patients should not create one themselves. Instead, it shows why the medicine does not disappear from the body the day after the final tablet and why the timing of a switch should be considered clinically.

Starting injections too aggressively based on a self-calculated conversion could potentially expose a patient to more semaglutide effect than expected, particularly while semaglutide from previous treatment remains present. On the other hand, creating a long unplanned gap could interrupt treatment and affect appetite control or weight-management progress.

The correct timing therefore requires more than matching milligrams. A prescriber may need to consider current tablet exposure, tolerability, treatment continuity and the dose of injection being considered.

This is also why patients should be cautious about online conversion charts. A chart suggesting that 1.5 mg, 4 mg, 9 mg or 25 mg tablets directly match specific weekly injection doses may give a false impression of precision where current UK prescribing information does not provide a universal conversion.

How a Switch From Wegovy Tablets to Injections May Be Planned

A prescriber will review current tablet strength, duration of use, adherence, side effects and other medicines before determining the appropriate injection starting dose and timing.

A switch from oral to injected Wegovy should begin with a review of the patient's actual current treatment, rather than simply the dose that appears on the most recent prescription.

A prescriber may ask questions such as:

• What Wegovy tablet strength are you currently taking?

• How long have you been at that dose?

• When was your last tablet taken?

• Have you missed multiple doses recently?

• Do you consistently follow the 8-hour fasting requirement?

• Do you wait 30 minutes before food, drink and other oral medicines?

• What side effects have you experienced?

• How has appetite and weight changed?

• Have you previously used Wegovy injections?

• Are you taking insulin, sulfonylureas or another medicine affecting blood glucose?

These questions matter because two people holding prescriptions for the same 25 mg tablet may not necessarily have identical semaglutide exposure. Oral absorption is variable and correct administration affects absorption.

Patients should also be honest about missed doses or difficulties following the tablet routine. Someone who frequently eats shortly after taking the tablet, drinks a large volume of water with it or misses doses may have a different treatment history from someone taking the same prescribed strength exactly according to instructions. This is clinically relevant information, not something to hide from the prescriber.

Once an injection plan has been prescribed, the practical routine changes significantly. Wegovy injections are administered once weekly, rather than once daily. They can be taken at any time of day, with or without meals, and are injected under the skin of the abdomen, thigh or upper arm.^[1][2]

The fasting rules used for the Wegovy pill do not apply to the injection. A patient switching to injections therefore no longer needs to:

• fast for at least 8 hours before each daily dose

• limit water to the amount specified for tablet administration

• wait 30 minutes before breakfast

• wait 30 minutes before taking other oral medicines because of the Wegovy tablet

However, the injection introduces different responsibilities. Patients need to use the device correctly, follow the instructions for their particular pen, rotate or appropriately select injection sites and dispose of needles safely where applicable.

The standard injection dose-escalation schedule is:

• Weeks 1–4: 0.25 mg once weekly

• Weeks 5–8: 0.5 mg once weekly

• Weeks 9–12: 1 mg once weekly

• Weeks 13–16: 1.7 mg once weekly

• Maintenance: 2.4 mg once weekly

For some adults with obesity, the current UK SmPC allows an increase to 7.2 mg once weekly where needed, after at least four weeks at 2.4 mg.

These are the approved injection escalation steps, but patients switching from tablets should not interpret this list as personalised instructions to restart at 0.25 mg or jump directly to a higher dose. The appropriate plan after oral treatment must be determined by the prescriber because the UK product information does not give a universal reverse conversion for each tablet strength.

The same applies to people who previously used injections. For example, someone who took 2.4 mg injections six months ago, subsequently used tablets and now wants to return to injections should not assume that their former 2.4 mg dose remains the correct restart dose. Treatment interruptions, side effects and current exposure all need consideration.

What to Expect After Changing From the Wegovy Pill to an Injection

Gastrointestinal side effects such as nausea and diarrhoea may continue after switching, and appetite suppression may feel different due to the distinct pharmacokinetic profile of subcutaneous semaglutide.

Switching from the Wegovy pill to an injection changes the route and frequency of treatment, but not the active ingredient. Both formulations contain semaglutide, so many of the expected effects and potential side effects overlap.

Common gastrointestinal side effects associated with semaglutide include nausea, diarrhoea, constipation and vomiting.^[2][8] A patient who experienced these problems on tablets may still experience them with injections. Switching formulation should not be viewed as a guaranteed way to eliminate side effects.

Equally, an individual's experience may change after the switch. Oral absorption is more variable, whereas subcutaneous administration produces a different pharmacokinetic profile. The UK SmPC warns that the effect of moving between formulations cannot easily be predicted, so appetite suppression or gastrointestinal symptoms may not feel exactly the same immediately after a change.^[1][2]

Patients should monitor how they feel and report severe or persistent adverse effects. Vomiting and diarrhoea can cause dehydration, which may be particularly important for people with kidney problems.

Severe, persistent abdominal pain requires urgent medical assessment, particularly where acute pancreatitis is suspected. Patients should not assume that intense unexplained abdominal pain is simply an expected part of changing formulations.

Sudden changes in vision also require urgent assessment. UK safety information for semaglutide includes a very rare risk of non-arteritic anterior ischaemic optic neuropathy (NAION), and sudden loss of vision, including partial loss of vision, should be assessed urgently by an eye specialist.^[9][10]

People with type 2 diabetes may require additional monitoring. Semaglutide can affect blood glucose, and the risk of hypoglycaemia can increase when used alongside insulin or sulfonylureas.^[11] A prescriber may need to review these medicines when planning treatment.

Semaglutide should not be used during pregnancy and should be stopped at least two months before a planned pregnancy because of its long half-life. Anyone who becomes pregnant or plans a pregnancy should contact their healthcare professional.

There are several practical reasons someone may prefer to switch from the pill to injections. The injection may suit a person who:

• finds daily medication difficult to remember

• struggles with the 8-hour fasting requirement

• wants to eat or drink immediately after waking

• takes several important oral medicines in the morning

• prefers once-weekly treatment

• is comfortable self-injecting

The pill may remain preferable for someone with significant needle anxiety or a strong preference for oral medication who can reliably follow the fasting instructions.

Convenience should therefore be judged realistically. A daily pill may initially sound easier than an injection, but the Wegovy tablet has stricter administration requirements. Conversely, a once-weekly injection avoids the daily fasting routine but requires comfort with injection technique and remembering the weekly dosing day.

In summary, switching from the Wegovy pill to an injection may be possible, but there is no simple universal tablet-to-injection conversion in current UK prescribing information. The fact that 2.4 mg injections can transition to 25 mg tablets does not mean the reverse should automatically be assumed. Oral semaglutide has variable absorption, semaglutide remains in the circulation for weeks, and the correct injection plan depends on individual treatment history.

Patients should therefore speak to a qualified prescriber before stopping Wegovy tablets, choosing an injection dose or deciding when to administer the first injection. A clinically supervised switch can take account of the current tablet strength, duration of treatment, adherence, tolerability, other medicines and the reason for changing formulation.

Scientific References

1. Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
2. Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
3. Semaglutide – British National Formulary (BNF / NICE).
4. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
5. First GLP-1 tablet for weight loss approved in the UK.
6. Rybelsus – EPAR product information (PDF).
7. Rybelsus 3 mg Tablet – Summary of Product Characteristics (SmPC).
8. Wegovy – EPAR product information (PDF).
9. Semaglutide (Wegovy, Ozempic and Rybelsus): risk of non-arteritic anterior ischaemic optic neuropathy (NAION).
10. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy).
11. Ozempic 0.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
12. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
13. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
14. Semaglutide: a medicine to manage type 2 diabetes or treat obesity.
15. Wegovy – Package Leaflet: Information for the Patient (PIL 13800).

Frequently Asked Questions